Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
1991 | 1 |
1995 | 2 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Minimal cardiac electrophysiological activity of alprenoxime, a site-activated ocular beta-blocker, in dogs.
Life Sci. 1995;56(14):1207-13. doi: 10.1016/0024-3205(95)00060-j.
Life Sci. 1995.
PMID: 7475898
No changes greater than 6% from baseline were detected with alprenoxime infusion. Similarly, no beta-antagonist cardiac activity could be detected in isoproterenol stimulated dogs after alprenoxime. The results demonstrate that alprenoxime has no significant …
No changes greater than 6% from baseline were detected with alprenoxime infusion. Similarly, no beta-antagonist cardiac activity coul …
Improved delivery through biological membranes. LVI. Pharmacological evaluation of alprenoxime--a new potential antiglaucoma agent.
Bodor N, Elkoussi A.
Bodor N, et al.
Pharm Res. 1991 Nov;8(11):1389-95. doi: 10.1023/a:1015849123020.
Pharm Res. 1991.
PMID: 1798675
A new site-specific chemical delivery system (CDS) for alprenolol was designed and investigated as a potential novel antiglaucoma agent. The effect of this compound, alprenoxime (AO), on the intraocular pressure (IOP) of rabbits was evaluated after its uni- and bilateral a …
A new site-specific chemical delivery system (CDS) for alprenolol was designed and investigated as a potential novel antiglaucoma agent. The …
Item in Clipboard
Sequential bioactivation of methoxime analogs of beta-adrenergic antagonists in the eye.
Bodor N, Prokai L, Wu WM, Somogyi G, Farag H.
Bodor N, et al.
J Ocul Pharmacol Ther. 1995 Fall;11(3):305-18. doi: 10.1089/jop.1995.11.305.
J Ocul Pharmacol Ther. 1995.
PMID: 8590263
The corresponding ketoxime analogs of the various beta-blockers were successfully applied and one of them, Alprenoxime, was tested in humans. The main problem with these compounds, however, is formulation stability: Alprenoxime has a t90 of only 2-3 months. ...
The corresponding ketoxime analogs of the various beta-blockers were successfully applied and one of them, Alprenoxime, was tested in …
Item in Clipboard
Cite
Cite